Overview
- The White House asks lawmakers to codify Most‑Favored‑Nation drug pricing deals, citing 16 manufacturer agreements negotiated since a 2025 executive order.
- Trump proposes routing federal support directly to individuals via health savings accounts rather than insurer subsidies, an approach Democrats criticize as insufficient, with no congressional sponsors identified.
- The plan pledges to restore cost‑sharing reduction payments, which the White House says could cut common ACA premiums by over 10% and save $36 billion, while analysts note potential ripple effects for other plan tiers.
- New transparency rules would require insurers to post plain‑English coverage comparisons, profits and claim‑denial rates, and would compel providers and insurers taking Medicare or Medicaid to publicly display prices.
- Trump touts a TrumpRx.gov portal and wider over‑the‑counter drug access, while outside reports flag sparse details and question his claim of 300%–500% price cuts and the timing of promised savings.